Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Topica Pharmaceuticals

Request full access

Topical antifungal treatment for fungal nail infections

Los Altos, United StatesFounded 2004Biotech & Life Sciences

About Topica Pharmaceuticals

Topica Pharmaceuticals, Inc. was a privately held, clinical-stage specialty pharmaceutical company founded in 2008 and based in Palo Alto, California. The company's primary focus was the development and commercialization of luliconazole, a topical antifungal agent, for the treatment of onychomycosis, which are fungal infections of the nail. The company's business model centered on in-licensing promising drug candidates and advancing them through clinical development in the Americas and Europe.

Topica in-licensed its lead product, luliconazole, from Nihon Nohyaku Co., Ltd. This antifungal agent was already approved and marketed in Japan for treating tinea infections. The company's strategy was to develop a 10% luliconazole solution specifically for onychomycosis, a condition affecting over 35 million Americans with limited effective and safe topical treatments. Luliconazole showed high potency and the ability to rapidly penetrate the nail plate to reach the infection in the nail bed. The company was led by President and CEO Greg Vontz.

The company successfully completed a Phase 1/2a clinical trial in 2011, which demonstrated the safety and tolerability of its luliconazole solution. Following these positive results, Topica Pharmaceuticals secured $27 million in a Series B financing round in October 2011, led by Third Rock Ventures, with participation from existing investors Prospect Venture Partners and Yasuda Enterprise Development Corporation. This funding was intended to support a large-scale Phase 2b/3 clinical trial starting in 2012, with the goal of gaining FDA approval. The company raised a total of at least $28.7 million across its funding rounds. According to PitchBook, the company went out of business in May 2016.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
23.7/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2013 $32M $126M Undisclosed —
SERIES BOther financing Oct 2011 $27M $108M Prospect Venture Partners · Yasuda Enterprise Development · Third Rock Ventures —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Topica Pharmaceuticals website traffic

Latest recorded traffic for Topica Pharmaceuticals is 0 monthly website visits.

Latest monthly visits0
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Topica Pharmaceuticals in the Los Altos ecosystem

Live from Dealroom

The Topica Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Los Altos HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Topica Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Topica Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.